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Results

Background
Baseline
Characteristics

Gabapentin group
(n=15)

Control Group
(n=30)

P-value

Age (yr), m (IQR)

52 (42-62)

56 (52-66)

0.29

Sex (male), n (%)

5 (16.7%)

25 (83.3%)

0.78

Daily alcohol intake, m
(IQR)

11.0 (7.0-22.0)(n=12)

7.5 (5.3-11.0)(n=27)

0.19
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History of AUD, n (%)

14 (93.3%)

24 (80.0%)

0.24

0

Clinical Outcomes

Gabapentin group
(n=15)

Control Group
(n=30)

P-value

Progression to severe
AWS, n(%)

1 (6.7%)

1 (3.3%)

1.00

Cumulative BZD*,
m (IQR)

4 (2.0-5.0)(n=11)

5 (1.5-9.0)(n=14)

0.91

Hospital LOS (hrs),
m (IQR)

102.8 (73.8-161.8)

85.3 (60.0-158.0)

0.39

ICU LOS (hrs), m (IQR)

44.6 (30.3-57.4)(n=3)

• Complicated alcohol withdrawal is associated with increased
in-hospital morbidity and mortality, length of stay, health
care costs, ventilator use and duration, and acute medical
and surgical complications.
• Benzodiazepines (BZDs) are 1st line agents for prophylaxis
for inpatients at risk of developing severe/complicated
withdrawal, but they pose a risk for over-sedation,
delirium, negative neurologic sequelae, and alcohol-BZD
codependence.
• There is a paucity of data regarding alternative prophylactic
agents to BZDs for patients who are not yet experiencing
signs of withdrawal.
• Gabapentin indirectly modulates GABA neurotransmission
by inhibiting voltage-dependent calcium channels leading to
anxiolytic, sedative, and anticonvulsive properties.

Determine the safety and efficacy of gabapentin as an add-on
prophylactic agent for preventing patient progression to severe
AWS and any associated complications in hospitalized patients
at risk of developing AWS.

Participants:
>18 years old hospitalized patients at risk of AWS
with initial Clinical Institute Withdrawal
Assessment for Alcohol (CIWA) scores <8
Exclusion criteria:
• Active withdrawal upon admission
• Initial CIWA >8
• BZD or gabapentin as a home medication
Groups:
Patients who received gabapentin prior to a
reported CIWA score >8 vs those that did not

Control

Gabapentin

Average Daily CIWA Scores
3
2
1
0

85.5 (70.0-100.0)(n=6)

m: mean; IQR: interquartile range; AUD: alcohol use disorder; ICU: intensive care unit
**lorazepam equivalence; **p<0.05 denotes statistical significance

Methodology
Design:
Single-center retrospective chart review
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• Gabapentin’s role as an adjunct in acute treatment of
alcohol withdrawal syndrome (AWS) has been established,
but its role in prophylaxis warrants further investigation.

Objective

Maximum Daily CIWA Scores

Primary endpoint:
Rate of progression from CIWA scores <8 to
severe AWS, defined as two CIWA scores >15
within an 8-hr time period
Secondary endpoints:
• Average and max patient CIWA scores
• Need for rescue medications
• Hospital and ICU length of stay (LOS)
• Rates of complications from AWS

0.03**
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Conclusion
• Our pilot study evaluating gabapentin for AWS prophylaxis found no differences in
progression to severe withdrawal, hospital LOS, need for rescue medications, BZD
requirements, or adverse effects. Median ICU LOS was shorter among patients who
received gabapentin.
• Gabapentin 300mg q 8H was the most commonly observed dosing regimen.
• Limitations: small sample size, retrospective design, combination of high and low risk
patients
• Larger prospective studies evaluating gabapentin prophylaxis in high-risk patients are
warranted. The lack of observed differences in our study may be attributed to the small
sample size and the combination of low- and high-risk patients.

• Adverse effects of gabapentin use
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